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Abstract
Introduction: No randomised, controlled trials have been conducted to date on the efficacy of psychological and
pharmacological treatments of pain catastrophising (PC) in patients with fibromyalgia. Our aim in this study was to
assess the effectiveness of cognitive-behaviour therapy (CBT) and the recommended pharmacological treatment
(RPT) compared with treatment as usual (TAU) at the primary care level for the treatment of PC in fibromyalgia
patients.
Methods: We conducted a six-month, multicenter, randomized, blinded, parallel group, controlled trial in which
patients were randomly assigned to one of three study arms: CBT (n = 57), RPT (n = 56) and TAU at the primary
care level (n = 56). The major outcome of this study was PC in patients with fibromyalgia. The secondary variables
were pain acceptance, depression, anxiety, pain, global function and quality of life.
Results: CBT significantly decreased global PC at the six-month follow-up examination with effect sizes of Cohen’s
d = 0.73 and 1.01 compared with RPT and TAU, respectively. CBT was also more effective than RPT and TAU at
increasing pain acceptance at the six-month follow-up examination (effect sizes of Cohen’s d = 0.77 and 0.80,
respectively). Compared with RPT and TAU, CBT was more effective at improving global function based on the
Fibromyalgia Impact Questionnaire (six-month effect sizes Cohen’s d = 0.44 and 0.53, respectively) and quality of
life based on the European Quality of Life Scale (six-month effect sizes Cohen’s d = 0.11 and 0.40, respectively).
There were no differences among the three treatments with regard to pain and depression.
Conclusions: CBT shows higher efficacy than RPT and TAU not only in key outcomes in FM, such as function and
quality of life, but also in relevant mediators of treatment effects, such as pain catastrophising and pain acceptance.
Trial registration: ISRCTN: ISRCTN10804772
Keywords: catastrophisation, fibromyalgia, randomised controlled trial, cognitive-behaviour therapy
Introduction
The role of pain catastrophising (PC) in mediating
responses to pain has received considerable attention in
recent years [1-3], and a consistent relation between PC
and distress reactions to painful stimulation has been
demonstrated [3]. Although the defining criteria for PC
have never been explicitly stated, there is general consen-
sus that this construct involves an exaggerated negative
orientation toward noxious stimuli. The aetiology of PC is
not clear. It has been demonstrated that interpersonal
mechanisms may not play a significant role in its develop-
ment [4], whereas insecure attachment is positively asso-
ciated with it [5]. Some of the consequences that have
been associated with PC are more intense pain [6], heigh-
tened pain behaviour [7-9], greater analgesic consumption
[10], reduced involvement in daily activities [3], occupa-
tional disability [11-13], suicidal ideation [14], increased
use of healthcare services and longer hospital stays [15,16].
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depression and catastrophism [4], but this construct is
different from the negative thoughts found in depression.
Depressive thoughts are present only when associated
with depressive mood; however, PC is considered a con-
tinuous psychological variable that is normally distribu-
ted even in healthy individuals without pain or
depression [17]. The kinds of cognitions that characterise
depression and catastrophism are also different: depres-
sive thoughts are related to depression and similar con-
cepts, such as inferiority, guilt or suicide. Catastrophising
cognitions are exclusively focused on pain: a negative
vision of it (magnification), continuously thinking about
it (rumination) and the impossibility of controlling it
(helplessness). A scale has been developed to measure
PC: the Pain Catastrophizing Scale (PCS) [6].
Fibromyalgia (FM) is a prevalent and disabling disorder
characterised by a history of widespread pain for at least
three months and patient-reported tenderness in at least
11 of 18 defined tender points when digitally palpated
with about 4 kg per unit area of force [18]. PC is a key
risk factor of FM; in fact, PC is one of the most com-
monly used classifications to differentiate the clinical
subtypes of FM [19]. PC occurs at higher rates in people
with FM compared with other rheumatologic popula-
tions. Moreover, there is often an even stronger relation-
ship between PC and key clinical outcomes, such as pain
intensity and pain sensitivity, in comparison with other
rheumatologic diseases [20-22].
However, despite the importance of PC, only one
study of the psychological treatment of patients with PC
has been conducted, and the only outcome assessed in
that study was the general satisfaction of the patient and
his or her knowledge about PC [23]. Our present study
was not a randomised, controlled trial. According to a
recent meta-analysis of the psychological interventions
in FM [24], only five randomised, controlled trials have
assessed PC as one of the outcomes [25-29]. To the best
of our knowledge, there have been no studies of the
pharmacological treatment of PC.
The aim of the present study was to assess the effec-
tiveness of cognitive-behaviour therapy (CBT) and the
recommended pharmacological treatment (RPT) for FM
and to compare them with treatment as usual (TAU) at
the primary care level for the treatment of PC in patients
with FM. The secondary objective was to determine how
depression, anxiety and pain contribute to predicting the
response of PC to CBT.
Materials and methods
Design
We conducted a six-month, multicentre, randomised,
parallel group, controlled trial in which patients were
randomly assigned to one of three study arms (ratio
1:1:1): CBT, RPT with pregabalin and an antidepressant
(duloxetine) if there was comorbid depression and (3)
TAU at the primary care level. Evaluators were blinded
to participants’ treatment group assignments. The proto-
col of this study has been previously published [30]. This
trial followed the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials, or IMMPACT,
recommendations for chronic pain clinical trials [31] and
the Consolidated Standards of Reporting Trials, or CON-
SORT, recommendations for randomised, controlled
trials [32]. No changes to the methods were made after
the trial began.
Setting and study sample
Patients were recruited from any of the 41 primary health-
care centres in the city of Zaragoza, Spain. Zaragoza is the
fifth-largest city in Spain, with a population of 713, 000.
This study was carried out from January 2009 to June
2010. Participants were recruited from January to Decem-
ber 2009, and the six-month follow-up examinations were
completed from January to June 2010. Patients were con-
secutively recruited by doctors working in primary care
centres until the required sample size was attained, with-
out a quota of patients assigned from each centre. Patients
considered for inclusion were 18 to 65 years of age, able to
understand and read Spanish, fulfilled the criteria for FM
according to the American College of Rheumatology [18],
had undergone no psychological treatment during the pre-
ceding two years, were receiving no pharmacological treat-
ment at that time or were willing to discontinue it for two
weeks before the start of the study, and had signed an
informed consent statement. Those excluded were
patients with severe axis I psychiatric disorders (dementia,
schizophrenia, paranoid disorder and alcohol and/or drug
abuse); patients with severe axis II psychiatric disorders or
other medical disorders that, from the clinician’s point of
view, prevented the patient from following the treatment
protocol; women who were pregnant or nursing; and
those who declined to participate.
Randomisation, treatment arms, implementation and
masking of the study groups
Randomisation
Each patient was assigned to one of the three groups by a
computer-generated random number sequence. Randomi-
sation was stratified by the existence of comorbid depres-
sion to ensure a balance of patients with depression in the
three groups.
Group assignment
The allocation sequence was generated by a member of
the research group who was not involved in the study.
Patients were automatically assigned to a group according
to the random allocation sequence. The sequence was
concealed until interventions were assigned. Patients
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without knowing which treatment they would receive.
Implementation
The family doctors recruited the patients and assessed
them for comorbidity of depression for stratification of the
sample. They were unaware of the allocation sequence
and were informed by telephone of the treatment group to
which the patient was assigned. Central telephone assign-
ment according to the computer-generated random alloca-
tion sequence was performed by a researcher with no
clinical involvement in the trial. The recruiting doctor
thus obtained each patient’s group assignment instantly by
telephone. RPT was administered by two psychiatrists
(JGC and MA), TAU was administered by family doctors,
and psychological interventions were delivered by trained
therapists (SM and BR). Study personnel who conducted
psychological assessments (RM and YLdH) were blinded
to participants’ treatment conditions. Owing to the charac-
teristics of the trial, patients and therapists who adminis-
tered any of the treatments were not blinded to the
treatment that patients received.
Intervention
Psychological intervention
We used a manual-based protocol derived from Thorn’s
model [33] that focuses on treating PC [34]. Our group
adapted this model to treat people with FM [35]. This
intervention was previously used and described in a pilot
study of the treatment of PC in patients with FM [26], and
its efficacy was assessed in a recent meta-analysis [24].
The CBT intervention mainly consists of two major
components: cognitive restructuring, which focuses on
reducing pain-specific dysfunctional cognitions (primarily
PC), and coping, which focuses on teaching cognitive and
behavioural coping strategies. In summary, this interven-
tion encompasses ten weekly 90-minute CBT group ses-
sions, including nine standard CBT sessions that are based
on Thorn’s program [33] and one specific session on PC
(session 8). The duration of the intervention is 10 to 12
weeks. The program is structured as follows. Session 1:
the connection between stress and pain. Session 2: identifi-
cation of automated thoughts. Session 3: evaluation of
automated thoughts. Session 4: questioning the automatic
thoughts and constructing alternatives. Session 5: nuclear
beliefs. Session 6: nuclear beliefs on pain. Session 7: chan-
ging coping mechanisms. Session 8: coping with rumina-
tions, obsessions and worrying. Session 9: expressive
writing. Session 10: assertive communication.
Session 8 is the additional PC session that begins after
the coping session. This session is directed especially at
participants who show high rumination. It consists of
instructing the patients to write a story regarding the
worst possible scenario for the future based on their great-
est fear. This story should stress aspects that generate the
greatest amount of malaise (for example, ‘How do you see
yourself in this situation?’, ‘What do you think?’, ‘How do
you feel?’, and so forth). The story is audiorecorded for a
subsequent presentation to the patient. Patients are
instructed to listen to this story for 30 to 60 minutes until
it no longer causes anxiety. In general, this process takes
between 10 and 15 sessions.
This treatment is highly structured and conducted in a
group format with a maximum of eight patients per
group. Because this psychotherapy program is strongly
structured and patient participation is emphasised and
focused on the task, the interactions among the patients
are limited. These groups do not allow for the type of
therapeutic interactions found in psychodynamic groups.
Trained therapists at the Torrero health centre adminis-
tered the psychotherapy. Random sessions were audiore-
corded and assessed by other members of the team to
confirm that CBT techniques were exclusively used.
Groups were consecutively created to fulfil the required
sample size. The patients were occasionally allowed to use
minor analgesics during the study, but not pregabalin,
gabapentin, opioids or antidepressants.
Recommended pharmacological treatment
In 2007, the US Food and Drug Administration (FDA)
approved pregabalin as the first drug to manage the
symptoms of FM in the United States. Within 18 months,
this agency also approved duloxetine and milnacipran for
the same purpose. Although these drugs are marketed in
Europe for other purposes, the European regulatory
authorities recently rejected extending their approval of
these drugs to include the treatment of FM [36]. On the
basis of FDA recommendations and the Spanish Consen-
sus for the Treatment of Fibromyalgia [37], treatment
with pregabalin (300 to 600 mg/day) and duloxetine (60
to 120 mg/day) was administered to patients with major
depressive disorder as diagnosed according to the Mini-
International Neuropsychiatric Interview (MINI). A psy-
chiatrist administered RPT and conducted follow-up
with patients at baseline and each month after baseline
during the six-month study.
Treatment as usual at the primary care level
The TAU group received the standard care offered by gen-
eral practitioners at their health centres. To improve this
group’s treatment, the doctors received the ‘Guide for the
Treatment of Fibromyalgia in Primary Care’ [38], which is
edited and distributed by the Aragonese Health Service.
‘Treatment as usual’ implies that doctors selected a phar-
macological treatment as well as the frequency of patient
visits that they considered adequate. However, the treat-
ment recommended in the guide that they received
matched that of the recommended pharmacological
intervention.
Neither the RPT patients nor the TAU patients received
any psychological intervention during the six-month trial.
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Measurements
The study personnel who carried out the measurements
were kept blinded to which treatment each patient
received. The assessments took place at baseline, post-
treatment and after one, three and six months. Posttreat-
ment assessment took place nine weeks after the baseline
assessment for all groups, because this was the amount of
time required for the CBT group to complete group
therapy.
Main outcome variables
The primary objective of this study was to assess the effi-
cacy of CBT, RPT and TAU for the treatment of PC in
patients with FM in primary care settings. The major out-
come of this study was PC in patients with FM. This con-
struct was assessed using the Spanish version [39] of the
PCS [6]. The PCS is a 13-item self-report questionnaire
that comprises three dimensions: rumination, magnifica-
tion and helplessness. There is no established ‘cutoff’
point, because PC is considered to be distributed in a con-
tinuous way in the general population. All items are rated
on a Likert scale from 0 (not at all) to 4 (all the time). The
total possible score ranges from 0 to 52, with a higher
score indicating higher PC.
Secondary variables
The secondary objectives of this study were to evaluate,
in patients with FM, the efficacy of CBT, RPT and TAU
in primary care for depression (measured using the
Hamilton Rating Scale for Depression (HAM-D)); anxi-
ety (assessed using the Hamilton Anxiety Rating Scale
(HARS)); pain (measured using the Pain Visual Analo-
gue Scale (PVAS)); global function (assessed using the
Fibromyalgia Impact Questionnaire (FIQ)); and quality
of life (assessed using the European Quality of Life Scale
5-D (EuroQol-5D) Questionnaire).
Sociodemographic variables
The following patient data were collected: gender, age,
marital status (single, married or in a relationship, sepa-
rated or divorced, or widowed), ethnic group, living
arrangements (alone, with spouse or partner, with off-
spring and/or spouse or partner, with other relatives, or
with others), educational level (no formal education, pri-
mary school, secondary school, or university), employment
status (unemployed, paid employment, on sick leave from
paid employment, retired/pensioner or permanent disabil-
ity), and income (measured using the minimum monthly
salary in Spain).
Clinical variables
The clinical variables considered were years since the diag-
nosis of FM, preference for psychotherapy, comorbid
depression, and sexual abuse and whether the patient was
e n g a g e di nl i t i g a t i o na tt h a tt i m e .
Psychiatric interview
Psychiatric disorders were diagnosed by conducting the
MINI psychiatric interview [40], an instrument devel-
oped for use in primary care settings.
Hamilton Rating Scale for Depression
The HAM-D is probably the most used interview-based
depressive symptom rating scale [41]. Although the origi-
nal scale had 21 items, Hamilton suggested scoring only
the initial 17 items because the last 4 items either occurred
infrequently or described only aspects of the illness. Items
are ranked on a scale of 0 to 4 (items with quantifiable
severity) or 0 to 2 (items that measure symptoms that are
more difficult to assess reliably). The greatest severity is
indicated by a score of 2 or 4. The range for the 17-item
scale is 0 to 50. The most used thresholds used are the fol-
lowing: very severe, > 23; severe, 19 to 22; moderate, 14 to
18; mild, 8 to 13; and normal, < 8 [42]. We used the vali-
dated Spanish version of HAM-D [43].
Hamilton Anxiety Rating Scale
The HARS is a clinician-administered rating scale that
consists of 14 items [44]. Each item is rated on a 5-point
scale (from 0 = no symptoms to 4 = severe, grossly dis-
abling symptoms). Total scores for the HAS range from 0
to 56. A score of 14 or greater has been suggested to indi-
cate clinically significant anxiety. We used the validated
Spanish version of HARS [45].
Pain Visual Analogue Scale
PVAS records the subject’s self-assessed pain on a Visual
Analogue Scale (VAS), a 10-cm vertical line numbered
from 0 to 100, with 0 representing no pain and 100
representing maximum pain [46].
Chronic Pain Acceptance Questionnaire
The Chronic Pain Acceptance Questionnaire (CPAQ) is
a 20-item inventory designed to measure the patient’s
acceptance of pain [47]. CPAQ measures two principal
factors: engagement in activities and pain willingness.
All items are rated on a 0 (never true) to 6 (always true)
scale. Nine items measuring pain willingness are
reverse-keyed. The maximum possible total score is 120,
with a higher score indicating better acceptance. The
validated Spanish version of CPAQ was used [48].
Fibromyalgia Impact Questionnaire
The FIQ is a 10-item self-report questionnaire developed
to measure the health status of FM patients [49]. The
first item focuses on the patient’s ability to carry out phy-
sical activities. In the next two items, patients are asked
to circle the number of days in the past week during
w h i c ht h e yf e l tg o o da n dh o wo f t e nt h e ym i s s e dw o r k .
Each of the last seven questions (job ability, pain, fatigue,
morning tiredness, stiffness, anxiety and depression) is
measured on a VAS. We used the translated and vali-
dated Spanish version of the FIQ [50].
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The EuroQol-5D (EQ-5D) questionnaire is a generic
instrument used to capture health-related quality of life
[51]. It has two parts. Part 1 records patients’ self-reported
problems in each of five domains: mobility, self-care, usual
activities, pain and/or discomfort and anxiety and/or
depression. Each domain is divided into three levels of
severity corresponding to no problems, some problems
and extreme problems. Part 2 records the subject’ss e l f -
assessed health on a VAS, a 10-cm vertical line on which
the best and worst imaginable health states are scored 100
and 0, respectively.
Statistical methods
Sample size
To calculate the sample size, it was necessary to know
the effectiveness of pharmacological and psychological
treatments on the main outcome variable: PC. There are
no prior published studies on the pharmacological treat-
ment of PC in FM. According to Glombiewski et al.’s
meta-analysis [24], the effect size (using Hedges’ g, a var-
iation of Cohen’s d that corrects for biases due to small
sample sizes) of psychological interventions on PC in
patients with FM ranges from 0.07 [12] to 1.9 [26].
Owing to this enormous variability, and on the basis of
previous studies [25-30], we aimed to detect a difference
of 25% or more between any of the groups (control and
intervention). Accepting an a risk of 0.05 and P = 80% in
a bilateral contrast, we needed 55 patients in each group
[52]. Calculating 5% of refusals as found in previous stu-
dies [25-30], we needed a sample size of 58, which
implies a total sample of 174 patients with FM.
Analysis strategy
All statistical analyses were performed using IBM SPSS
Statistics version 19.0 software (IBM Corp, Armonk, NY,
USA). First, we compared the sociodemographic and clini-
cal characteristics of the three groups to verify that there
were no significant differences among them at baseline.
We used means ± SD for the continuous variables and
percentages for the categorical variables. For comparisons,
we used analysis of variance (ANOVA) for continuous
variables (with post hoc Tukey’s honestly significant differ-
ence test) and Χ
2 test with continuity corrections (or 2 × 2
Fisher’s exact test when appropriate) for categorical
variables.
In the present work, participants who provided a base-
line and at least one posttreatment measurement com-
prised the intention-to-treat population. The outcomes
were analysed using the last observation carried forward
method. After the Kolmogorov-Smirnov test was per-
formed to assess distributions for normality, analysis of
covariance (ANCOVA) that included baseline scores as
covariates was performed to examine the differences
among the PC scale total scores of the three groups
posttreatment and at the six-month follow-up examina-
tion for each of the PCS domains (rumination, magnifica-
tion and helplessness) and secondary variables (CPAQ,
HAM-D, HARS, PVAS, FIQ and EQ-5D). ANCOVA has
greater statistical power than ANOVA to detect changes
from baseline in randomised designs [53]. We selected the
Bonferroni method to adjust the significance level of sub-
sequent pairwise contrasts. The one- and three-month fol-
low-up data were not analysed, because we focused only
on the main assessment period (that is, posttreatment and
the six-month follow-up).
The overall a level was set at 0.05. We also report the
effect sizes (that is, the omnibus partial hp
2 value). In this
case, hp
2 can be interpreted as the proportion of variance
in the outcome that is attributable to each effect. The rule
of thumb for hp
2 is that 0.01 is small, 0.06 is medium and
0.14 is large. Additionally, we computed Cohen’s d for
each pairwise comparison. The rule of thumb for Cohen’s
d is that 0.20 is small, 0.50 is medium and 0.80 is large.
Ethical aspects of the study
This study followed Helsinki Convention norms and later
modifications and the Declaration of Madrid of the World
Psychiatric Association. The study protocol was approved
by the Ethical Review Board of Aragon. All patients pro-
vided their written informed consent before the com-
mencement of any study activities or procedures.
Results
Sample recruitment
A total of 218 patients were screened, and 49 were
excluded (Figure 1). Of these 49 patients, 30 were ineligi-
ble because they did not meet the entry criteria, 16
decided not to participate, 3 were impossible to contact
and 169 were enrolled. Of the patients enrolled, 57 were
randomly assigned to the CBT group, 56 to the RPT
group and 56 to the TAU group. All of them received the
allocated intervention (N = 168), except one patient in the
TAU group who moved to another city during the study
period. A total of 141 patients (83.9%) completed the
study, comprising 49 (85.9%) in the CBT group, 46
(82.1%) in the RPT group and 46 (83.6%) in the TAU
group (Figure 1). The patients’ reasons for discontinuation
were as follows. In the CBT group, one patient (1.7%) did
not complete the study due to lack of efficacy of the treat-
ment, four patients (7%) due to a personal decision and
three patients (5.2%) were lost to follow-up. In the RPT
group, three patients (5.3%) withdrew due to adverse
effects of the treatment (two due to digestive problems
and the other due to dizziness), three patients (5.3%) due
to a personal decision and four patients (7.1%) were lost to
follow-up. In the TAU group, two patients (3.6%) with-
drew due to adverse events, two patients (3.6%) due to a
personal decision, three patients due to lack of efficacy
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three groups did not differ significantly with regard to the
percentage of patients who completed the study or to the
reasons for discontinuation.
Baseline demographic and clinical characteristics
The sample was mainly made up of middle-aged, mar-
ried European females who lived with a spouse and/or
offspring, had a primary or secondary school education,
Assessed for eligibility 
(N=218) 
Recommended pharmacological treatment 
(RPT) 
- Allocated to intervention (N=56) 
- Received allocated intervention (N=56) 
- Did not receive allocated intervention (N=0) 
Excluded (N=49) 
- Unable to contact (N=3) 
- Declined to participate (N=16) 
- Did not meet inclusion criteria (N=30) 
     - Age > 65 (N=3) 
     - Diagnosis of FM not based on ACR criteria (N=5) 
     - Did not understand Spanish (N=2) 
     - Previous psychotherapy treatment (N=4) 
     - Did not agree to discontinue pharmacological treatment (N=16) 
Cognitive behaviour therapy (CBT) 
- Allocated to intervention (N=57) 
- Received allocated intervention (N=57) 
- Did not receive allocated intervention (N=0) 
    
Number of sessions received 
      - Received 9 sessions (N=43) 
      - Received 8 sessions (N=5) 
      - Received 7 sessions (N=6) 
      - Received 6 sessions (N=2) 
      - Received 1 session (N=1) 
Randomised 
(N= 169) 
Treatment as usual (TAU) 
- Allocated to intervention (N=56) 
-  Received allocated intervention (N=55) 
- Did not receive allocated intervention 
(N=1). Reason: Moved to another city 
 
POST-TREATMENT 
Followed up N=56 
POST-TREATMENT 
Followed up N=53 
POST-TREATMENT 
Followed up N=53 
1-MONTH FOLLOW-UP 
Followed up N=54 
1-MONTH FOLLOW-UP 
Followed up N=51 
1-MONTH FOLLOW-UP 
Followed up N=50 
6-MONTH FOLLOW-UP 
Followed up N=46 
6-MONTH FOLLOW-UP 
Followed up N=49 
6-MONTH FOLLOW-UP 
Followed up N=46 
3-MONTH FOLLOW-UP 
Followed up N=49 
3-MONTH FOLLOW-UP 
Followed up N=51 
3-MONTH FOLLOW-UP 
Followed up N=48 
ANALYSED N= 49 
Excluded from analysis N=0 
ANALYSED N= 46 
Excluded from analysis N=0 
ANALYSED N= 46 
Excluded from analysis N=0 
Withdrawal due to 
adverse events: N= 3 
Withdrawal due to 
patient decision: N= 2 
Withdrawal due to lack 
of efficacy: N= 3 
Withdrawal due to 
patient decision: N= 2 
Withdrawal: N= 2 
Patient decision: N= 1 
Lost to follow-up: N=1 
Withdrawal due to lack 
of efficacy: N= 1 
Withdrawal due to 
adverse events: N= 2 
Withdrawal due to 
patient decision: N= 2 
Withdrawal: N=3 
Patient decision: N= 2 
Lost to follow-up: N=1 
Withdrawal due to 
loss to follow-up: N=2  Withdrawal due to 
loss to follow-up: N=2 
Withdrawal due to 
loss to follow-up: N=3 
ENROLLMENT 
ALLOCATION 
FOLLOW-UP 
ANALYSIS 
Figure 1 Flowchart of the study.
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Page 6 of 13were unemployed or on sick leave and had a low or
medium income level. From a clinical point of view, the
patients, on average, had had FM for more than ten
years. Half of them had been diagnosed with major
depressive disorder, more than 10% had experienced
sexual abuse and about 25% were currently engaged in
litigation (Table 1). There were no statistically signifi-
cant differences in baseline demographics or clinical
characteristics between the three treatment groups,
except for income, which was lower in the TAU group
(Table 1). The questionnaire scores at baseline revealed
that the participants had high PC, low pain acceptance,
moderate depression, severe pain, limited global func-
tion and low quality of life (see Table 2). Moreover, the
patients’ anxiety levels were not clinically significant.
There were significant differences (P < 0.05) between
the groups with regard to acceptance and anxiety at
baseline. Post hoc comparisons indicated that the CBT
group had higher acceptance scores than the RPT and
TAU groups (Cohen’s d = 0.48 and 0.43, respectively).
In addition, the RPT group had significantly higher
anxiety than the TAU group (Cohen’s d = 0.50).
Effectiveness in the main outcome: pain catastrophising
Table 2 displays the means ± SD for all outcome vari-
ables at baseline, posttreatment and the six-month fol-
low-up. As shown in the right column, the ANCOVA
yielded significant effects for global PC and the three
PCS dimensions (rumination, magnification and help-
lessness). The pairwise comparisons yielded the same
pattern of results for all PCS dimensions. After treat-
ment, we found that CBT had been more effective than
the other two treatments in reducing PC, rumination,
magnification and helplessness. These improvements
were still observed at the six-month follow-up. In addi-
tion, we found that RPT was more effective than TAU
at reducing all of the PCS dimensions.
Effectiveness in secondary outcomes
ANCOVA revealed significant effects (see Table 2) of pain
acceptance (CPAQ), depression (HAM-D), anxiety
(HARS), pain (PVAS), functional impairment (FIQ) and
health-related quality of life (EuroQol VAS). Pairwise com-
parisons within the pain acceptance findings indicated that
the patients who received CBT had improved more at the
posttreatment and six-month follow-up examinations than
those assigned to other treatments. There were no signifi-
cant differences between the groups with regard to depres-
sion posttreatment; however, we found that depression
had reduced more in the CBT group than in the TAU
g r o u pa tt h es i x - m o n t hf o l l o w - u p .C B Ta n dR P Tw e r e
equally effective at reducing anxiety: Both treatment
options were significantly better than TAU posttreatment
and at the six-month follow-up. There were no significant
differences in pain level between the groups posttreat-
ment. Pain levels had reduced more for the RPT group
than for the TAU group by the six-month follow-up. An
analysis of functional impairment revealed a group effect
that favoured the CBT group posttreatment and at the six-
month follow-up. We observed a group effect of the Euro-
Qol VAS, such that patients who received CBT showed
more improvement than those treated with RPT or TAU
posttreatment and at the six-month follow-up.
Discussion
Characteristics of the study
To the best of our knowledge, this is the first study to
assess the efficacy of CBT, RPT and TAU in reducing PC
in patients diagnosed with FM. Only five previous rando-
mised, controlled trials assessed the efficacy of treatments
on PC in FM patients [26-30], but none of them consid-
ered PC as the main outcome. Other strengths of this
study are the assessment of the influences of variables
such as depression, anxiety or pain on the variations in
PC. These results can be generalised because of the high
external validity of the sample study (recruited in primary
care settings). One of the main limitations of the study is
the number of secondary variables analysed, which raises
the concern of obtaining a significant result by chance
(type I error). However, because of the lack of similar stu-
dies and the range of possible outcomes in FM [30], we
considered it appropriate to use several different outcome
measures.
Treatment efficacy in terms of the main outcome: pain
catastrophising
CBT significantly decreased global PC at the six-month
follow-up, with effect sizes of Cohen’s d = 0.73 and 1.01
compared with RPT and TAU, respectively. Previous stu-
dies in which the effectiveness of CBT in reducing PC in
FM patients was assessed found effect sizes ranging from
0.17 [29] and 0.26 [25] up to a maximum of 0.56 [29]. The
effect sizes in our study are similar to those found in pre-
vious studies on the efficacy of CBT in FM patients and in
a meta-analysis of psychological and pharmacological
treatments for FM administered at primary and secondary
levels of healthcare [30]. However, our current study is the
first to assess the effectiveness of CBT compared with
RPT and TAU on reducing the three subscales of PC. It
confirms that CBT was significantly more effective than
the other two treatments.
In some previous studies, comparison of CBT with pla-
cebo therapies for the treatment of PC in FM patients pro-
duced inconsistent results. For instance, in Vlaeyen et al.’s
study [29], CBT was less effective (effect size 0.17) than
education (effect size 0.27). In our study, we found that
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Page 7 of 13Table 1 Baseline sociodemographic and clinical characteristics of patients with fibromyalgia by treatment group
Sociodemographic variables Cognitive behaviour therapy group
(N = 57)
RPT group
(N = 56)
TAU group
(N = 55)
Statistics
Females, n (%) 54 (94.7%) 52 (92.9%) 53 (96.4%) X2 = 0.674
df =3
P = 0.714
Mean age, years (± SD) 46.35 (6.71) 47.12 (6.25) 47.04 (6.53) F = 0.240
df = 165
P = 0.787
Marital status, n (%) X2 = 0.279
df =4
P = 0.991
Married or in a relationship 40 (70.2%) 40 (71.4%) 37 (67.3%)
Single 9 (15.8%) 9 (16.1%) 10 (18.2%)
Separated or divorced 8 (14%) 7 (12.5%) 8 (14.5%)
Widowed 0 (0%) 0 (0%) 0 (0%)
Ethnic group, n (%) P =1
European 57 (100%) 57 (100%) 57 (100%)
Living arrangement, n (%) X2 = 1.481
df =8
P = 0.993
Living alone 4 (7.0%) 4 (7.1%) 6 (10.9%)
Living with spouse or
partner
8 (14.0%) 9 (16.1%) 8 (14.5%)
Living with offspring
and/or spouse/partner
34 (59.6%) 30 (53.6%) 31 (56.4%)
Living with other relatives 5 (8.8%) 7 (12.5%) 5 (9.1%)
Other 6 (10.5%) 6 (10.7%) 5 (9.1%)
Educational level, n (%) X2 = 1.578
df =4
P = 0.813
Illiterate 0 (0%) 0 (0%) 0 (0%)
Primary school 23 (40.4%) 23 (41.1%) 28 (50.9%)
Secondary school 23 (40.4%) 22 (39.3%) 18 (32.7%)
University 11 (19.3%) 11 (19.6%) 9 (16.4%)
Employment status, n (%) X2 = 1.295
df =8
P = 0.996
Unemployed 19 (29.8%) 15 (26.8%) 15 (27.3%)
Paid employment 9 (15.8%) 11 (19.6%) 9 (16.4%)
On sick leave from paid
employment
13 (22.8%) 12 (21.4%) 14 (25.5%)
Retired/pensioner 7 (12.3%) 6 (10.7%) 8 (14.5%)
Permanent disability 11 (19.3%) 12 (21.4%) 9 (16.4%)
Income X2 = -10.04
df =4
P = 0.40
< MS (600€/month) 15 (26.3%) 15 (26.8%) 27 (49.1%)
1 to 2 MS 24 (42.1%) 23 (41.1%) 20 (36.4%)
> 2 to 4 MS 18 (31.6%) 18 (32.1%) 8 (14.5%)
> 4 MS 0 (0%) 0 (0%) 0 (0%)
Clinical variables
Mean years since
diagnosis (± SD)
12.91 (7.15) 11.23
(3.85)
11.69
(4.02)
F = 1.544
df = 165
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(Continued)
P = 0.217
Preference for
psychotherapy, n (%)
28 (49.1%) 26 (46.4%) 27 (49.1%) X2 = 0.107
df =2
P = 0.948
Comorbid major
depressive disorder, n (%)
27 (47.4%) 26 (46.4%) 30 (54.5%) X2 = 0.874
df =2
P = 0.646
Sexual abuse, n (%) 4 (7.0%) 7 (12.5%) 11 (14.5%) X2 = 1.70
df =2
P = -0.427
Currently engaged in
litigation, n (%)
17 (29.8%) 12 (21.4%) 16 (29.1%) X2 = 1.23
df =2
P = 0.539
MS = minimum salary; RPT = recommended pharmacological treatment; TAU = treatment as usual group.
Table 2 Analyses of covariance (modified intention-to-treat analysis by last observation carried forward method) for
mean scores on primary and secondary outcome measures by group at baseline, posttreatment and six-month follow-
up
Outcome measures Mean
CBT
(± SD)
Mean
RPT
(± SD)
Mean
TAU
(± SD)
F-
value
P-
value
hp
2 Pairwise
comparisons
Cohen’s d
CBT vs
RPT
Cohen’s d
CBT vs
TAU
Cohen’s d
RPT vs
TAU
PCS total score (0 to 52)
Baseline 34.13 (9.29) 32.19 (7.05) 31.23 (7.18)
Posttreatment 24.79 (7.41) 31.36 (7.10) 31.47 (6.90) 133.34 0.001 0.63 1 < 2, 3 0.91 0.93 0.02
Six-month follow-
up
25.50 (7.24) 30.64 (6.75) 32.74 (7.04) 144.33 0.001 0.65 1 < 2 < 3 0.73 1.01 0.30
PCS-Rumination (0 to
16)
Baseline 11.87 (3.08) 11.08 (2.57) 10.92 (2.77)
Posttreatment 8.82 (2.47) 10.68 (2.53) 11.09 (2.60) 100.82 0.001 0.56 1 < 2, 3 0.74 0.90 0.16
Six-month
follow-up
9.02 (2.46) 10.28 (2.50) 11.34 (2.61) 87.82 0.001 0.53 1 < 2 < 3 0.51 0.91 0.42
PCS-Magnification
(0 to 12)
Baseline 6.38 (2.63) 6.23 (2.40) 5.92 (2.22)
Posttreatment 5.18 (2.27) 6.15 (2.48) 6.19 (2.23) 33.08 0.001 0.30 1 < 2, 3 0.41 0.45 0.02
Six-month
follow-up
5.59 (2.32) 6.34 (2.42) 6.62 (2.27) 23.65 0.001 0.23 1 < 2 < 3 0.32 0.45 0.12
PCS-Helplessness
(0 to 24)
Baseline 15.89 (5.07) 14.89 (3.98) 14.57 (4.13)
Posttreatment 10.79 (4.04) 14.55 (3.98) 14.36 (3.99) 74.29 0.001 0.49 1 < 2, 3 0.94 0.90 0.05
Six-month
follow-up
10.95 (4.01) 14.02 (3.85) 14.94 (4.27) 68.04 0.001 0.46 1 < 2 < 3 0.78 0.96 0.23
CPAQ (0 to 120)
Baseline 49.00
(10.33)
44.40 (8.90) 44.45
(10.80)
Posttreatment 51.30 (9.53) 43.36 (9.00) 43.15
(10.86)
33.07 0.001 0.29 1 > 2, 3 0.86 0.80 0.02
Six-month
follow-up
50.46 (9.37) 43.47 (8.85) 42.53
(10.40)
24.97 0.001 0.24 1 > 2, 3 0.77 0.80 0.10
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RPT was more effective than TAU in the reduction of all
PCS dimensions.
Effectiveness in terms of the secondary outcomes
CBT is more effective than RPT or TAU, both at post-
treatment and at the six-month follow-up, for the fol-
lowing secondary outcomes measured in this study: pain
acceptance, anxiety, global function and quality of life.
However, CBT is not more effective than the other two
interventions at reducing depression and pain.
CBT was more effective than RPT and TAU at increas-
ing pain acceptance at the six-month follow-up (effect
sizes of Cohen’s d = 0.77 and 0.80, respectively). This
report is one of the first to study the effectiveness of CBT
in treating pain acceptance, a key concept of third-wave
therapies, especially Acceptation and Commitment Ther-
apy (ACT) [54]. ACT proposes that attempting to control
internal events such as pain sensations and negative
emotional reactions is problematic. ‘Pain acceptance’ is a
psychological construct that refers to the process of
learning to live with pain. Although we have described
the components of the psychotherapy, we did not include
ACT elements. We hypothesise that CBT increases pain
acceptance because it promotes the acquisition of diverse
skills needed to manage pain. For instance, cognitive
restructuring enhances coping (by reframing) and might
affect pain acceptance. Indeed, a previous study found
great similarities between a behavioural coping strategy
(that is, task persistence) and pain acceptance [55].
Regarding depression, there are no differences among
the three treatments in decreasing depression either post-
treatment or at the six-month follow-up. This is not sur-
prising, because patients in the pharmacological and
TAU groups who were diagnosed with depression on the
basis of the MINI psychiatric interview used antidepres-
sants according to treatment guidelines [37,38]. Many
studies have demonstrated that pharmacological and
Table 2 Analyses of covariance (modified intention-to-treat analysis by last observation carried forward method) for
mean scores on primary and secondary outcome measures by group at baseline, posttreatment and six-month follow-
up (Continued)
HAM-D (0 to 50)
Baseline 14.47 (3.93) 14.94 (4.03) 14.09 (4.64)
Posttreatment 7.78 (2.46) 7.98 (1.80) 8.17 (2.25) 2.17 0.12 0.03 ns 0.09 0.17 0.09
Six-month
follow-up
7.91 (2.50) 8.19 (1.96) 8.57 (2.47) 4.05 0.02 0.05 1 < 3 0.12 0.27 0.17
HARS (0 to 56)
Baseline 10.84 (4.27) 11.22 (3.75) 9.50 (2.98)
Posttreatment 7.09 (2.96) 7.11 (2.39) 7.40 (2.18) 9.71 0.001 0.11 1, 2 < 3 0.01 0.12 0.13
Six-month
follow-up
7.25 (3.02) 7.39 (2.57) 7.58 (2.07) 8.49 0.001 0.10 1, 2 < 3 0.05 0.13 0.08
PVAS (0 to 100)
Baseline 64.20
(10.78)
68.13 (9.84) 64.72
(10.44)
Posttreatment 36.88 (8.29) 37.14
(10.53)
38.68 (7.48) 2.25 0.109 0.03 ns 0.03 0.23 0.17
Six-month
follow-up
40.68
(10.93)
40.54 (9.61) 44.34 (8.56) 7.48 0.001 0.09 2 < 3 0.01 0.37 0.42
FIQ (0 to 100)
Baseline 65.91
(10.85)
66.36 (9.88) 64.48
(10.50)
Posttreatment 46.21 (9.18) 50.93 (9.38) 48.64 (6.77) 6.96 0.001 0.08 1 < 2, 3 0.51 0.30 0.28
Six-month
follow-up
48.80 (9.11) 52.84 (9.17) 53.26 (7.54) 11.22 0.001 0.12 1 < 2, 3 0.44 0.53 0.05
EuroQol VAS (0 to 100)
Baseline 44.55
(16.47)
46.82
(15.62)
43.87
(14.50)
Posttreatment 60.45
(16.63)
58.00
(13.07)
53.49
(14.40)
11.49 0.001 0.13 1 > 2, 3 0.16 0.45 0.33
Six-month
follow-up
58.39
(16.27)
56.73
(13.85)
52.26
(14.03)
10.44 0.001 0.12 1 > 2, 3 0.11 0.40 0.32
CBT = cognitive-behaviour therapy; CPAQ = Chronic Pain Acceptance Questionnaire; EuroQol VAS = EuroQol Visual Analogue Scale; FIQ = Fibromyalgia Impact
Questionnaire; HAM-D = Hamilton Rating Scale for Depression; HARS = Hamilton Anxiety Rating Scale; PCS = Pain Catastrophizing Scale; PVAS = Pain Visual
Analogue Scale; RPT = recommended pharmacological treatment; TAU = treatment as usual. ns = nonsignificant difference between groups (P > 0.05).
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depression [30]. Researchersi nm o s tp r e v i o u ss t u d i e so f
CBT in FM patients have found effect sizes of about 0.3
to 0.4, with some outliers reaching 1.22 [25]. Some inves-
tigators have found CBT to be ineffective for treating
depression in FM patients [29]. Another meta-analysis
concluded that the efficacy of CBT in treating depression
could not be distinguished without some risk of bias [56].
In our study, CBT was effective for decreasing depres-
sion, but RPT and TAU were also quite effective, so we
found no significant differences among the three.
In our study, CBT and RPT improved anxiety symptoms
significantly more than did TAU. All patients in the phar-
macological group were treated with pregabalin, a drug
that is effective for both pain and anxiety. In addition,
about 50% of patients in this group who were diagnosed
with depression took antidepressants that are also effective
for anxiety. We do not think this is due to low effective-
ness of CBT, because previous studies of anxiety have con-
firmed that it is effective [57]. Instead, we believe that this
result was obtained because TAU is effective in reducing
anxiety. It is difficult to compare these results with those
of previous studies, because anxiety is not usually an out-
come of interest for psychological interventions in FM
patients [25,30].
In our study, CBT did not improve pain (as assessed by
PVAS) more than the other two treatments either post-
treatment or at the six-month follow-up. Only RPT is
more effective than TAU at six months. Previous studies
of CBT in FM patients [24] have found effect sizes of
0.35 to 0.5 for pain. In our study, all of the patients in the
RPT arm took pregabalin, a potent analgesic, and over
half of them also took duloxetine, which, in addition to
being an antidepressant, has an analgesic effect. It seems
that for pain, CBT cannot overcome the effect of RPT.
The lesser effectiveness of TAU can be attributed to
many family doctors’ not systematically using pregabalin
to treat FM patients or duloxetine to treat patients with
associated depression.
For patients with FM, CBT, compared with RPT and
TAU, was more effective at improving global function
as assessed by the FIQ (six-month effect sizes Cohen’s d
= 0.44 and 0.53, respectively) and quality of life as
assessed by the EuroQol VAS (six-month effect sizes:
Cohen’s d = 0.11 and 0.40, respectively). Previous stu-
dies of CBT in FM patients [24] have found effect sizes
of 0.2 to 0.5 based on the FIQ [24]. However, a recent
meta-analysis in which quality of life was assessed [56]
suggested that CBT is not effective for the achievement
of this outcome. CBT may be more effective than other
treatments at changing these two variables because they
are global assessments of the patient, and CBT is more
able than pharmacological approaches to improve many
aspects of FM.
How pharmacotherapy might improve PC has not
been discussed herein, thus only tentative suggestions
can be proposed to explain our results. The current
conceptualisations of pain incorporate a biopsychosocial
approach that involves behavioural reactions (for exam-
ple, avoidance behaviour), cognitive reactions (for exam-
ple, PC) and physiological reactions (for example,
elevated autonomic arousal and muscle tension). These
approaches are highly related and establish a vicious
cycle [58]. RPT improves behavioural and physiological
reactions [59], thus their effects might indirectly affect
cognitive reactions (that is, PC).
Conclusions
Our present study confirms that PC, an important out-
come in patients with FM [24-29], significantly
improved after CBT compared with RPT or TAU. CBT
also improved other relevant outcomes, such as pain
acceptance, anxiety, global function and quality of life.
On the basis of the results of our study, and from a clin-
ical point of view, we can recommend that clinicians
systematically include CBT in the management of
patients with FM. It may not be so advisable to include
CBT in the treatment of FM from a cost-effectiveness
point of view, as researchers in some meta-analyses have
found [56]. In fact, investigators in some meta-analyses
[30] did not observe differences between standard pri-
mary care treatments and more specialised approaches
delivered at the secondary level. In any case, new rando-
mised, controlled trials with larger samples are necessary
to definitively decide the role of CBT in the standard
care of patients with FM.
Despite the overall high efficacy of CBT, new research
should focus on improving this efficacy even more.
Some interesting future directions include the early
detection and treatment of patients who are at risk of
developing FM [60], considering ‘stage of chronicity’ as
a moderator of vulnerability [48] and subdividing FM
patients according to their distinctive, contextual cogni-
tive-behavioural patterns [19].
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